

Amendments to the Claims:


Please amend claims 1, 7-12, 23-25, and 27 as shown in the listing of claims.

Please cancel 5, 6, 14-22, 26, 28-58, 62, and 63 without prejudice.

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method for treating a pathological condition of ocular tissue, comprising contacting a therapeutically active complex with ocular tissue, wherein the therapeutically active complex is 1-O-hexadecyloxypropyl-phospho-arabinofuranosylguanosine (HDP-P-Ara-G), 1-O-hexadecylcycloxypropyl-cyclic-cidofovir (HDP-cCDV) or hexadecyloxypropyl-3-phospho-ganciclovir (HDP-P-GCV), has the structure I:




wherein the pathological condition is selected from the group consisting of macular degeneration, ~~eye trauma, a pre-existing retinal detachment,~~ ocular proliferative or vascular diseases, ~~or and~~ diseases of elevated intraocular pressure, ~~wherein in structure I:~~

~~each of R₁ and R₁' is independently selected from the group consisting of H, an optionally substituted O(C₁-C₂₄)alkyl, O(C₁-C₂₄)alkenyl, O(C₁-C₂₄)acyl, S(C₁-C₂₄)alkyl, S(C₁-C₂₄)alkenyl, and S(C₁-C₂₄)acyl, wherein at least one of R₁ and R₁' is not H, and wherein the alkenyl or acyl optionally has between 1 and 6 double bonds,~~

~~each of R₂ and R₂' is independently selected from the group consisting of H, an optionally substituted O(C₁-C₇)alkyl, O(C₁-C₇)alkenyl, S(C₁-C₇)alkyl, S(C₁-C₇)alkenyl, O(C₁-C₇)acyl, S(C₁-C₇)acyl, N(C₁-C₇)acyl, NH(C₁-C₇)alkyl, N((C₁-C₇)alkyl)₂, oxo, halogen, NH₂, OH, and SH;~~

X is



~~L is selected from the group consisting of a valence bond and a bifunctional linking group of the formula J (CR₂)_t G, wherein t is an integer having the value between 1 and 24, each of J and G is independently selected from the group consisting of O, S, C(O)O, and NH, and R is selected from the group consisting of H, substituted or unsubstituted alkyl, and alkenyl;~~

~~R₃ is a phosphate or phosphonate derivative of a therapeutically active agent;~~

~~m is an integer having the value between 0 and 6; and~~

~~n is 0 or 1;~~

thereby treating the pathological condition.

2-6. (Canceled).

7. (Currently Amended) The method of claim 1, wherein the therapeutically active complex has a particle size from about 10 nm up to 100,000 nm.

8. (Currently Amended) The method of claim 1, wherein the therapeutically active complex has a particle size from about 500 nm up to 100,000 nm.

9. (Currently Amended) The method of claim 1, wherein the therapeutically active complex has a particle size from about 500 nm up to about 50,000 nm.

10. (Currently Amended) The method of claim 1, wherein the therapeutically active complex is in a slurry comprising amorphous forms and crystalline forms.

11. (Currently Amended) The method of claim 1, wherein the therapeutically active complex is in substantially crystalline form.

12. (Currently Amended) The method of claim 1, wherein the therapeutically active complex is in substantially amorphous form.

13-22. (Canceled).

23. (Currently Amended) A method for the slow-release delivery of a therapeutically active ~~complex of claim 1~~ agent to ocular tissue, comprising contacting the ocular tissue with ~~a complex of a therapeutically active agent~~ complex, wherein the therapeutically active complex is 1-O-hexadecyloxypropyl-phospho-arabinofuranosyl-guanosine (HDP-P-Ara-G), 1-O-hexadecylcycloxypropyl-cyclic-cidofovir (HDP-cCDV) or hexadecyloxypropyl-3-phospho-ganciclovir (HDP-P-GCV), wherein the therapeutically active complex comprises particles having size between about 10 nm and about 100,000 nm, thereby delivering a slow-release of the therapeutically active agent to ocular tissue.

24. (Currently Amended) A method for increasing residence time of a therapeutically active agent in ocular tissue, comprising ~~forming the therapeutically active complex of claim 22, and~~ contacting ~~the a~~ a therapeutically active complex with ocular tissue, wherein the therapeutically active complex is 1-O-hexadecyloxypropyl-phospho-arabinofuranosylguanosine (HDP-P-Ara-G), 1-O-hexadecylcycloxypropyl-cyclic-cidofovir (HDP-cCDV) or hexadecyloxypropyl-3-phospho-ganciclovir (HDP-P-GCV), thereby increasing residence time of the therapeutically active agent in ocular tissue.

25. (Currently Amended) The method of ~~any one of claims 1, 22, or claim~~ claim 23 or claim 24, wherein the therapeutically active agent is for treating a pathological condition

of ocular tissue, wherein the pathological condition is selected from a the group consisting of macular degeneration, ocular proliferative or vascular diseases, and eye trauma diseases of elevated intraocular pressure.

26. (Canceled).

27. (Currently Amended) The method of claim 1, wherein the ~~therapeutically active agent is selected from the group consisting of adefovir, cidofovir, cyclic cidofovir, tenofovir, a derivative of azidothymidine, an anti-neoplastic nucleoside, and an antibody or a fragment thereof, and wherein the pathological condition is selected from the group consisting of macular degeneration, eye trauma, and a pre-existing retinal detachment.~~

28-63. (Canceled).